We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) to evaluate the impact of switching from a CNI-based to an mTOR inhibitor-based immunosuppressive regimen on the incidence of cSCC in KTRs with prior cSCC. The gene discussed is MTOR; the disease is skin squamous cell carcinoma.